A systematic review reveals that GLP-1 receptor agonists not only address psychotropic-induced metabolic disorders but also may positively impact mental wellbeing.
Researchers tracked suicidal behavior in early schizophrenia and found four distinct patterns linked to depression, delayed treatment, and childhood trauma.
A randomized trial of 248 hospitalized patients with alcohol use disorder found no significant difference in drinking reduction between oral and injectable naltrexone.
New research found patients with atopic dermatitis are up to 3 times more likely to experience depression and anxiety, especially when disease severity is high, and sleep is disrupted.
April’s FDA approvals feature first-in-class therapies, targeted biologics, expanded indications, and innovative delivery systems across allergy, endocrinology, rheumatology, oncology, infectious diseases, and more.